From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|October 13, 2021
Daily Medication Pearl: Solriamfetol (Sunosi) for Excessive Daytime Sleepiness
Author(s)Saro Arakelians, PharmD
The mechanism of action of solriamfetol is mediated through its activity as a dopamine and norepinephrine reuptake inhibitor indicated for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
Advertisement
Medication Pearl of the Day: Solriamfetol (Sunosi)
Indication: Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).
Insight:
- Dosing: Starting dose for patients with narcolepsy is 75 mg once daily. Starting dose for patients with OSA is 37.5 mg once daily. Dose may be increased at intervals of at least 3 days. Maximum dose is 150 mg once daily.
- Dosage form: Tablets 75 mg (functionally scored) and 150 mg.
- Adverse events (AEs): Most common AEs are headache, nausea, decreased appetite, insomnia, and anxiety.
- Mechanism of action: The mechanism of action of solriamfetol is thought to be mediated through its activity as a dopamine and DNRI.
- Manufacturer: Jazz Pharmaceuticals
Sources:
Advertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
4
Glucose Monitoring: Timing Makes Every Reading Count
5